menu
    • menu
    [{"orgOrder":0,"company":"Aeovian Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AV078","moa":"mTORC1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Aeovian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeovian Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aeovian Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aeovian Pharmaceuticals","sponsor":"Hevolution Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"AV078","moa":"mTORC1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Aeovian Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Aeovian Pharmaceuticals \/ Hevolution Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Aeovian Pharmaceuticals \/ Hevolution Foundation"},{"orgOrder":0,"company":"Aeovian Pharmaceuticals","sponsor":"Luma Group | CTI Life Sciences Fund | Foresite Capital | SymBiosis | TSC Alliance Endowment Fund | Wilson Sonsini | Apollo Health Ventures | Hevolution | Sofinnova Investments | venBio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"AV078","moa":"mTORC1","graph1":"Neurology","graph2":"Phase I","graph3":"Aeovian Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Solution","sponsorNew":"Aeovian Pharmaceuticals \/ Luma Group | CTI Life Sciences Fund | Foresite Capital | SymBiosis | TSC Alliance Endowment Fund | Wilson Sonsini | Apollo Health Ventures | Hevolution | Sofinnova Investments | venBio","highestDevelopmentStatusID":"6","companyTruncated":"Aeovian Pharmaceuticals \/ Luma Group | CTI Life Sciences Fund | Foresite Capital | SymBiosis | TSC Alliance Endowment Fund | Wilson Sonsini | Apollo Health Ventures | Hevolution | Sofinnova Investments | venBio"}]

    Find Clinical Drug Pipeline Developments & Deals by Aeovian Pharmaceuticals

    Menu

    Aeovian Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aeovian Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Aeovian Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV078

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Luma Group | CTI Life Sciences Fund | Foresite Capital | SymBiosis | TSC Alliance Endowment Fund | Wilson Sonsini | Apollo Health Ventures | Hevolution | Sofinnova Investments | venBio

                            Deal Size : $55.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Aeovian Pharmaceuticals Raises $55 Million for mTORC1 Inhibitor in Tuberous Sclerosis Complex-Related Epilepsy

                            Details : The Series B financing for AV078, a miscellaneous product targeting mTORC1, will advance treatment for Tuberous sclerosis complex (TSC)-related refractory epilepsy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 16, 2025

                            Lead Product(s) : AV078

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Luma Group | CTI Life Sciences Fund | Foresite Capital | SymBiosis | TSC Alliance Endowment Fund | Wilson Sonsini | Apollo Health Ventures | Hevolution | Sofinnova Investments | venBio

                            Deal Size : $55.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aeovian Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Aeovian Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV078

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Hevolution Foundation

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Aeovian Doses First Participants in Phase 1 Trial, Raises $50 Million Financing

                            Details : Proceeds will support AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor, with Phase 2 trials planned for adult and pediatric patients suffering from TSC refractory epilepsy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 28, 2024

                            Lead Product(s) : AV078

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Hevolution Foundation

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aeovian Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Aeovian Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV078

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers

                            Details : AV078 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : AV078

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.